Analysts Offer Insights on Healthcare Companies: Argenx Se (ARGX), IGC Pharma (IGC) and Fresenius Medical Care AG & Co. KGaA (GB:0H9X)
Express News | Ascendiant Capital Maintains Buy on IGC Pharma, Raises Price Target to $3.5
Express News | IGC Pharma Inc : Ascendiant Capital Markets Raises Target Price to $3.50 From $3.25
IGC Pharma Announces Equity Analyst Coverage by Alliance Global Partners (AGP) With a "Buy" Recommendation and $3.50 Price Target
A. G. P. Initiates IGC Pharma(IGC.US) With Buy Rating, Announces Target Price $3.5
Express News | President Biden X Post Says "I'm Making Sure No One Goes to Jail for Mere Use or Possession of Marijuana, and Their Records Should Be Expunged. It's Time We Right Those Historic Wrongs."
IGC Pharma Price Target Announced at $3.50/Share by Alliance Global Partners
Express News | IGC Pharma Inc : Alliance Global Partners Initiates Coverage With Buy Rating; Target Price $3.5
Express News | IGC Pharma Inc: Preliminary Analysis Confirms Presence of Tgr-63 in Brain Tissue and Shows No Adverse Effects
Express News | Preclinical Analyses of Tgr-63 Demonstrate Blood-Brain Barrier Permeability and Safety Profile
Preclinical Analyses of TGR-63 Demonstrate Blood-Brain Barrier Permeability and Safety Profile
Express News | IGC Pharma Annonuces Mouse Studies Showing Reduction In Amyloid Plaque With TGR-63: 78% In Cortex And 85% In Hippocampus
Express News | IGC Pharma Inc: Expects to Begin a Phase 1 Trial for Tgr-63 in 2025
Express News | IGC Pharma Inc: Mouse Studies Demonstrate Significant Reduction in Amyloid Plaque: 78% In Cortex and 85% in Hippocampus
Express News | IGC Pharma's Tgr-63 Preclinical Results Show Substantial Reduction in Amyloid Plaque, a Key Hallmark of Alzheimer's Disease
IGC Pharma Q4 2024 GAAP EPS $(0.04), Sales $295.000K Beat $193.000K Estimate
India Globalization Capital GAAP EPS of -$0.22 In-line, Revenue of $1.35M Beats by $0.11M
Express News | IGC Reports Financial Results for Fiscal Year Ended March 31, 2024
IGC Pharma | 10-K: Annual report
Express News | Ascendiant Capital Reiterates Buy on IGC Pharma, Maintains $3.25 Price Target